Clinical trial with arginine tidiacicate in symptomatic chronic persistent hepatitis.
In a double-blind study, 50 patients with chronic persistent hepatitis were assigned at random to two treatment groups. One group was given arginine tidiacicate (ATCA) at the dose of 400 mg tablets three times a day and the other given a placebo, both for 30 days. The group of patients receiving ATCA showed a clear-cut improvement of subjective symptoms and of the most important cytolysis and cholestasis parameters studied, such modifications being greater than in the placebo group. Drug tolerance was excellent, since no side-effects were observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001120:Arginine / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006505:Hepatitis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D053778:Thiazolidines
D053778:Thiazolidines; C020213:arginine thiazolidinecarboxylate; D001120:Arginine